{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:00:23Z","timestamp":1793520023347,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ymgme.2023.108119","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T08:03:36Z","timestamp":1703232216000},"page":"108119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease"],"prefix":"10.1016","volume":"141","author":[{"given":"Daniel","family":"Kenney-Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Korlimarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail A.","family":"Spiridigliozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Malinzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Nichting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Al Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanika","family":"Phornphutkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Provenzale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.108119_bb0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/8904_2015_426","article-title":"Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2023.108119_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.108119_bb0015","article-title":"Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1727","key":"10.1016\/j.ymgme.2023.108119_bb0020","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2023.108119_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","author":"Li","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.108119_bb0030","doi-asserted-by":"crossref","first-page":"100591","DOI":"10.1016\/j.ymgmr.2020.100591","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2023.108119_bb0035","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet. Med."},{"issue":"3, Supplement","key":"10.1016\/j.ymgme.2023.108119_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.01.566","article-title":"OP016: Mini-COMET: safety and efficacy of \u226597 weeks\u2019 avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa","volume":"24","author":"Kronn","year":"2022","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2023.108119_bb0045","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.108119_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2017.04.014","article-title":"Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up","volume":"121","author":"Spiridigliozzi","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2023.108119_bb0055","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1212\/WNL.0000000000009979","article-title":"Novel approaches to quantify CNS involvement in children with Pompe disease","volume":"95","author":"Korlimarla","year":"2020","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.ymgme.2023.108119_bb0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1203\/01.pdr.0000233014.84318.4e","article-title":"Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy","volume":"60","author":"Chien","year":"2006","journal-title":"Pediatr. Res."},{"issue":"6","key":"10.1016\/j.ymgme.2023.108119_bb0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.pediatrneurol.2010.02.006","article-title":"Acute progression of neuromuscular findings in infantile Pompe disease","volume":"42","author":"Burrow","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2023.108119_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/8904_2017_46","article-title":"Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset Pompe?","volume":"39","author":"Broomfield","year":"2018","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2023.108119_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2023.108119_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"13","key":"10.1016\/j.ymgme.2023.108119_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.108119_bb0090","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.ymgme.2018.12.214","article-title":"Quantitative evaluation of white matter hyperintensities in the central nervous system in infantile Pompe disease","volume":"126","author":"Korlimarla","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.108119_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.108119_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/apc.APC_171_18","article-title":"Normal reference ranges for the left ventricular mass and left ventricular mass index in preterm infants","volume":"13","author":"Abushaban","year":"2020","journal-title":"Ann. Pediatr. Cardiol."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.108119_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2017.05.006","article-title":"High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108119_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.569153","article-title":"Multicentric retrospective evaluation of five classic infantile Pompe disease subjects under enzyme replacement therapy with early Infratentorial involvement","volume":"11","author":"Paoletti","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2023.108119_bb0115","article-title":"Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: a case study","author":"Cer\u00f3n-Rodr\u00edguez","year":"2021","journal-title":"Mol. Genet. Genomic Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.108119_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gim.2022.10.005","article-title":"Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease","volume":"25","author":"Hsu","year":"2023","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2023.108119_bb0125","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/WNL.57.5.906","article-title":"Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2","volume":"57","author":"Martini","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.ymgme.2023.108119_bb0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","article-title":"Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase","volume":"269","author":"van Capelle","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.108119_bb0135","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human \u03b1-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics."},{"issue":"3","key":"10.1016\/j.ymgme.2023.108119_bb0140","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-022-11506-z","article-title":"Diffusion tensor imaging of the brain in Pompe disease","volume":"270","author":"van den Dorpel","year":"2023","journal-title":"J. Neurol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:37:15Z","timestamp":1729229835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223007497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1096719223007497"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108119","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108119"}}